Teva Pharmaceutical Industries Ltd. said Wednesday its third-quarter net income fell 13 percent, and the world's largest maker of generic drugs narrowed its 2011 earnings forecast.
The Israeli company earned $916 million, or $1.03 per share, in the three months that ended Sept. 30. That compares with $1.05 billion, or $1.15 per share, in the same quarter last year. Revenue climbed 2.2 percent to $4.34 billion.
Adjusted earnings were $1.25 per share.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
